J&J Is Quietly Dismantling Its Startup Incubator Empire

When you're writing checks that big, a network of small incubators starts to look like a rounding error. J&J generated over $25 billion in oncology sales last year and is planning to spin off its entire orthopedics business by late 2026. The company is clearly betting that concentrated, high-dollar bets on proven science will deliver more than nurturing dozens of seed-stage startups.

It's the difference between planting a thousand seeds in a garden and buying a fully grown orchard.

Big Pharma's Incubator Hangover

J&J isn't the only giant pulling back from the startup nursery. Pfizer recently shut down its Ignite business unit, which provided R&D services to early-stage biotechs. Meanwhile, the early-stage biotech landscape is littered with casualties: Rampart Bioscience ceased operations in recent months. Even well-funded companies aren't immune; Arena BioWorks cut 30% of its staff just 19 months after launching with $500 million.

The pattern is hard to miss. When funding gets tight, the ecosystem that supports young companies starts to crack. Incubators close. Startups fold. The pipeline of future drugs gets a little thinner.

There's an ironic twist here. Eli Lilly is moving in the opposite direction, expanding its incubator presence with a new site in South Korea. One pharma giant's trash, apparently, is another's strategic priority.

What Happens to the Startups Left Behind?

The New York Genome Center (NYGC), which houses the JLABS space, will take over management of the facility. But NYGC hasn't said a word about what happens next: whether current residents can stay, whether the space will remain a biotech incubator, or whether it'll be converted into something else entirely.

That silence is deafening for the startups currently working out of the SoHo location.

New York does have alternatives, though none carry J&J's brand or network. BioInc at New York Medical College in Westchester offers wet lab space on a health sciences campus. SUNY Downstate's Biotechnology Incubator in Brooklyn provides labs for early-stage firms. Upstate, the CNY Biotech Accelerator at Syracuse recently expanded its capacity. And just across the river in New Jersey, the Incubator at North Brunswick offers 46,000 square feet of plug-and-play lab space (alumni include Advaxis).

The infrastructure exists. But losing a JLABS site isn't just about square footage; it's about losing a direct pipeline to one of the world's largest pharmaceutical companies.

The Bigger Picture

J&J's projected 2026 revenue sits around $100 billion. The company secured 51 regulatory approvals in 2025, filed 32 new submissions, and kicked off 11 new Phase 3 programs. By any measure, the innovation machine is running hot.

But innovation at J&J increasingly looks like it happens through acquisition, not incubation. Buy the winners instead of growing them. It's a perfectly rational strategy for a company of J&J's size. It's also a strategy that assumes someone else will do the messy, expensive work of getting startups from napkin sketch to Series A.

The question nobody at J&J seems eager to answer: if every big pharma company adopts this approach, who exactly is going to build the companies they want to buy?

For now, the SoHo lights stay on under new management. But the name on the door has changed, and the phone number that connected scrappy founders to one of the world's largest pharmaceutical companies no longer rings.

The Eye Drug That Just Can't Take a Hint

Aldeyra Therapeutics just received its third FDA rejection for dry eye drug reproxalap, with regulators once again citing inconsistent efficacy data. The stock plunged over 70%, and Wall Street is running out of patience for a drug that keeps failing the same test.